Retina
experience
redefined
RETINA EXPERIENCE
Our retina experience will redefine your retina experience
Our team has unmatched expertise and an impressive track record of innovation in retinal disease
clinical trials designed or led by our team
combined years of treating patients with retinal disease
treatment launches across retinal disease
DISEASE BURDEN
Retinal disease is one of the leading causes of blindness1,2
9M
Americans3
Diabetic Retinopathy (DR)
1.8M
Americans3
Wet-Age Related Macular Degeneration (AMD)
1.5M
Americans3
Retinal Vein Occlusion (RVO)
TREATMENT BURDEN
Treatments for retinal disease create significant burden on patients and care partners4,5
WET AMD
The burden of wet AMD treatment can impact patients, care partners, and long-term outcomes4,5
Patient Burden
90% of patients currently require injections every 1-3 months, impacting and disrupting lives4,6
Care Partner Burden
Up to 12 days off from work per year may be needed from care partners for injection or treatment visits6
Poor Long-Term Outcomes
Frequent injections may result in retinal fluid fluctuations and decreased adherence, which are associated with poor long-term outcomes4,7
DIABETIC RETINOPATHY
Non-proliferative diabetic retinopathy (NPDR) patients are typically working adults, making frequent injections burdensome and often unsustainable8,9
REDEFINING TREATMENT
Ocular aims to transform the
treatment of retinal disease
We aim to reduce the therapeutic burden so more patients can stay on treatment...
in the hope of preserving vision for the long term.
AXPAXLI™ (also known as OTX-TKI), an investigational axitinib hydrogel administered by intravitreal injection, is currently in Phase 3 clinical trials for wet AMD
DISEASE BURDEN
Retinal disease is one of the leading causes of blindness
1.8M
Americans3
Wet Age-Related Macular Degeneration (AMD)
1.5M
Americans3
Retinal Vein Occlusion (RVO)
TREATMENT BURDEN
Treatments for retinal diseases create significant burden on patients and care partners4,5
WET AMD
The burden of wet AMD treatment can impact patients, care partners, and long-term outcomes4,5
Patient Burden
90% of patients currently require injections every 1-3 months, impacting and disrupting lives14,19
Care Partner Burden
Up to 12 days off from work per year may be needed from care partners for treatment visits19
Poor Long-Term Outcomes
Frequent injections may result in decreased adherence and retinal fluid fluctuations, which are associated with poor long-term outcomes21
DIABETIC RETINOPATHY
Non-proliferative diabetic retinopathy (NPDR) patients are typically working adults, making frequent injections burdensome and often unsustainable8,9
REDEFINING TREATMENT
Ocular aims to transform the treatment of retinal disease
We aim to reduce the therapeutic burden so more patients can stay on treatment…in the hope of preserving vision for the long term.
Ocular’s investigational therapy, AXPAXLITM (axitinib intravitreal hydrogel), also known as OTX-TKI, is currently in Phase 3 clinical trials for wet AMD
Read our
latest news
Explore our
pipeline
Learn about
upcoming events
References
1. Wang W, et al. Int J Mol Sci. 2018;19(6):1816. 2. Di Carlo E, et al. J Clin Med. 2021;10(15):3297. 3. Market Scope. 2025 Exudative Retinal Disease Pharmaceuticals Market Report. St. Louis, MO: Market Scope, LLC. 2025. 4. Gualino V, et al. J Fr Ophtalmol. 2020;43:1047-1053. 5. Varano M, et al. Clin Ophthalmol. 2016;10:257-267. 6. Market Scope. Ophthalmic Market Trends: Quarterly US Retina Edition. St. Louis, MO: Market Scope, LLC. 2025 7. Evans RN, et al. JAMA Ophthalmol. 2020;138(10):1109. 8. Sivaprasad S, et al. Eye. 2025;39(7):1234–1242. 9. Centers for Disease Control and Prevention. VEHSS Modeled Estimates: Prevalence of Diabetic Retinopathy (DR). Published February 5, 2025. Accessed December 3, 2025. https://bit.ly/4rDWxrZ.